Mark Weiser, MD
Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Corresponding author: Mark Weiser. MD, Department of Psychiatry, Sheba Medical Center, Tel-Hashomer, 52621, Israel ([email protected]).
Original Research
Add-on Pramipexole for Schizophrenia
August 1, 2022
Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
Original Research
Raloxifene in Postmenopausal Women With Schizophrenia
August 23, 2017
The estrogen protection hypothesis of schizophrenia was introduced in the late 1980s to explain gender-related differences in epidemiology and clinical features. This study examines whether raloxifene, an estrogen agonist,...
